Visual hallucinations (VH) are a core clinical feature of Dementia With Lewy Bodies (DLB), occurring in approximately 60-90% of patients and representing one of the most distinctive neuropsychiatric manifestations of the synucleinopathies[1]. Unlike the visual distortions seen in other dementias, DLB-associated VH are characteristically well-formed, detailed, and often feature people, animals, or objects that are experienced with full conviction and emotional engagement[2].
The neurobiology of VH in DLB is multi-factorial, arising from the convergence of cholinergic dysfunction, visual processing impairment, attentional dysregulation, and brainstem pathology that disrupts the normal gating of visual perception. Critically, visual symptoms — including VH and milder visual disturbances — often manifest years before the onset of dementia, making them critical prodromal markers for early DLB identification[3][4].
The leading cognitive model for VH in DLB is the attention-perception (A-P) framework, which proposes that VH arise from a failure of visual perception due to impaired bottom-up visual processing combined with compensatory over-recruitment of top-down attention[5][6]. In this model:
VH in DLB involve dysfunction across multiple interconnected regions[7]:
| Region | Pathology Type | Contribution to VH |
|---|---|---|
| Primary visual cortex (V1) | Alpha-synuclein, reduced activity | Reduced sensory input, "noise" in visual stream |
| Inferotemporal cortex | Tau, alpha-synuclein | Impairs object recognition and categorization |
| Ventral visual stream | Alpha-synuclein | Disrupts form and face processing |
| Dorsal visual stream | Lewy body inclusions | Impairs spatial localization of objects |
| Superior colliculus | Alpha-synuclein, cell loss | Fails to suppress competing stimuli |
| Pedunculopontine nucleus (PPN) | Cholinergic neuron loss | Loss of cortical arousal and sensory gating |
| Locus coeruleus | Noradrenergic neuron loss | Impaired attention and salience assignment |
| Nucleus basalis of Meynert | Cholinergic neuron loss | Reduced cortical activation for sensory processing |
| Retina | Alpha-synuclein, RNFL thinning | Direct visual pathway impairment |
The cholinergic system plays a central role in VH pathogenesis in DLB. Cholinergic deficits are among the most severe of any neurodegenerative condition, exceeding even Alzheimer's disease in some regions[8].
The NbM provides the primary cholinergic innervation to the neocortex. In DLB:
The PPN is the major cholinergic nucleus of the brainstem reticular activating system. PPN degeneration in DLB:
Cholinergic inputs to the visual cortex (from NbM) modulate:
When these modulatory inputs are lost, the visual system operates with reduced capacity to distinguish actual sensory input from internally generated predictions, creating the conditions for VH.
Visual symptoms in DLB often precede frank VH by years, providing a window for early identification[3:1][4:1]:
The prodromal phase typically evolves through:
The 2020 DLB consensus criteria recognize visual symptoms as part of the prodromal DLB category:
Visual symptoms are considered supportive features in prodromal DLB, particularly when combined with RBD and preserved memory.
Charles Bonnet Syndrome (CBS) — complex visual hallucinations in visually impaired individuals — shares significant mechanistic overlap with VH in DLB, providing important insights into the underlying neurobiology[10].
| Feature | CBS | DLB VH |
|---|---|---|
| Primary cause | Visual deprivation (peripheral) | Neurodegeneration (central) |
| Hallucination content | Similar (people, animals, patterns) | Similar |
| Insight | Often preserved | Often preserved early |
| Cholinergic involvement | Unclear | Central role |
| Predictive coding | Over-recruitment of predictions | Over-recruitment of predictions |
| Brainstem gating | May be intact | Impaired |
Both CBS and DLB VH support the view that visual perception is fundamentally predictive — the brain constantly generates predictions about the visual world and compares them against incoming sensory data. When sensory input is reduced (due to eye disease in CBS) or degraded (due to neurodegeneration in DLB), predictions are less constrained by reality and can break through into conscious awareness as hallucinations.
The critical difference between CBS and DLB VH is:
REM sleep behavior disorder (RBD) is the single most specific prodromal marker for DLB, and shares a common pathophysiological basis with VH[@surak2022][4:2].
Both RBD and VH arise from the same brainstem nuclei that degenerate early in the synucleinopathies:
The retina provides a unique window into DLB pathology, as it is the only part of the CNS directly observable in vivo. Retinal changes in DLB serve as biomarkers for VH and disease progression[11][12].
| Finding | Significance for VH |
|---|---|
| Peripapillary RNFL thinning | Global cholinergic degeneration; correlates with VH severity |
| Ganglion cell-inner plexiform layer (GCIPL) thinning | Specific to inner retinal layers affected by alpha-synuclein |
| Macular ganglion cell loss | Predicts VH occurrence and severity |
| Foveal thinning | Visual acuity impairment in DLB |
| Reduced macular vessel density | Microvascular dysfunction in DLB |
Retinal biomarkers complement other DLB markers:
| Biomarker Modality | Measure | VH Relevance |
|---|---|---|
| Retinal OCT | RNFL, GCIPL thickness | Structural correlates of VH severity |
| CSF alpha-synuclein RT-QuIC | Seed amplification | Reflects synuclein burden, predicts VH |
| CSF NfL | Neurofilament light chain | General neurodegeneration, correlates with VH |
| DaTSCAN/SPECT | Dopamine transporter imaging | Supports DLB diagnosis, indirect VH relevance |
| FDG-PET | Glucose metabolism | Visual cortex hypometabolism in VH |
Content: DLB VH are characteristically well-formed and detailed:
Temporal pattern:
Insight:
Patients with VH in DLB typically show:
VH in DLB must be distinguished from:
| Treatment | Mechanism | Efficacy for VH |
|---|---|---|
| Rivastigmine | Cholinesterase inhibitor | Strong evidence — reduces VH frequency and severity; only FDA-approved for PD dementia |
| Donepezil | Cholinesterase inhibitor | Moderate evidence; widely used off-label |
| Galantamine | Cholinesterase inhibitor | Some evidence; also has nicotinic effects |
| Quetiapine | Atypical antipsychotic | Limited evidence; risk of cerebrovascular events |
| Pimavanserin | 5-HT2A inverse agonist | FDA-approved for PD psychosis; emerging DLB data |
| Clonazepam | Benzodiazepine | For RBD, not VH |
| Melatonin | Hormone | For RBD, minimal VH effect |
Key principle: Antipsychotics (typical and many atypical) should be AVOIDED in DLB due to severe neuroleptic sensitivity — risk of fatal parkinsonism exacerbation.
Predictive coding validation: Can we directly measure the prediction-error signals that theoretically underlie VH? Do DLB patients show the predicted signature of excessive top-down prediction?
Retinal alpha-synuclein as biomarker: Can seed amplification or other assays detect retinal alpha-synuclein in living patients? Would this predict VH occurrence?
Prodromal identification: Which prodromal visual symptoms best predict eventual VH? Can we build a prodromal VH risk score combining retinal OCT, visual evoked potentials, and clinical measures?
Treatment targeting: Beyond cholinesterase inhibitors, what novel targets could address VH? PPN stimulation? Targeted cholinergic agents? Predictive coding modulators (e.g., NMDA antagonists)?
Overlap with CBS: Can studying CBS inform VH treatment in DLB? Could enhancing sensory input reduce VH in both conditions?
RBD-VH co-treatment: Can a single intervention address both RBD and VH? The shared brainstem pathophysiology suggests this should be possible.
Visual cortex rehabilitation: Could visual training or transcranial stimulation reduce VH by strengthening bottom-up processing?
Neuroimaging signatures: Do DLB patients with VH show specific patterns of functional connectivity disruption (e.g., default mode network — visual cortex dysconnection)?
McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2020. ↩︎ ↩︎
Walker Z, et al. Visual hallucinations in Lewy body disease: a systematic review of the literature and implications for clinical practice. Current Opinion in Neurology. 2015. ↩︎
Erdal F, et al. Prodromal visual disturbances in Lewy body diseases. Movement Disorders. 2023. ↩︎ ↩︎
Donaghy PC, et al. Prodromal DLB: the importance of REM sleep behavior disorder and visual symptoms. Neurology. 2022. ↩︎ ↩︎ ↩︎
Collerton D, et al. A new attention-based model of visual hallucinations in Alzheimer's disease. Neuropsychology. 2005. ↩︎
Morroni A, et al. Synaptic and neuropathological correlates of visual hallucinations in neurodegenerative disease. Acta Neuropathologica Communications. 2020. ↩︎
Ffytche DH, et al. The psychosis spectrum in Lewy body diseases. Brain. 2017. ↩︎
Dott S, et al. Visual hallucinations in Parkinson's disease: the cholinergic hypothesis and the role of the pedunculopontine nucleus. Journal of Neural Transmission. 2021. ↩︎ ↩︎ ↩︎
Serotaz M, et al. Cholinergic system integrity in visual processing regions in DLB and its relation to visual hallucinations. Brain. 2023. ↩︎
Kumar S, et al. Charles Bonnet syndrome in neurodegenerative disease: shared mechanisms with visual hallucinations in DLB. Journal of Neurology. 2025. ↩︎ ↩︎
Chen J, et al. Retinal biomarkers in Lewy body diseases: optical coherence tomography and fundus autofluorescence findings. Neurology. 2024. ↩︎ ↩︎
Rombos A, et al. Retinal layer thinning in DLB and PD: correlation with visual hallucinations severity. Ophthalmology. 2024. ↩︎ ↩︎